Page results
-
Neurosurgery is a treatment option for some people with epilepsy.
-
This service is unique in the UK, offering an adolescent rheumatology service that provides diagnostic and therapeutic advice to patients with any rheumatic diseases that occur in adolescence.
-
This leaflet explains the support a transition coordinator at the Adolescent Rheumatology Department provides, and how they can help.
-
Concerned about the impact of climate change on people with neurological conditions, Professor Sanjay Sisodiya has established established a consortium of neurological specialists and will be undertaking research.
-
Information for patients and visitors on patient isolation.
-
This information is for patients, (and their family and carers), who are considering having Uterine Artery (Fibroid) Embolisation (UAE). It explains what is involved and the possible risks.
-
It is important to make sure you are eating and drinking well before your surgery. Good nutrition will also help you recover after your surgery.
-
This page provides information about anaesthesia for children having proton beam therapy.
-
This page has been written for patients who are having a course of superficial radiotherapy for a skin tumour (such as a basal cell carcinoma or squamous cell carcinoma), or some other skin condition.
-
UCLH works in partnership with GPs in Barnet and Enfield to provide a community based ear, nose and throat (ENT) service. The Community ENT service provides specialist advice and treatment for a range of minor ENT conditions.
File results
-
FOI/2022/0194 - Drug treatment for lung cancer
-
FOI/2022/0199 - Trust postal service and patient communication
-
FOI/2022/0200 - IT budget/ chatbots
-
FOI/2022/0205 - Spending on communication activities
-
FOI/2022/206 - Rates for Bonham Carter House 52-54 Gower Street
-
FOI/2022/0207 - Patient treatment with Nivolumab
-
FOI/2022/0209 - Patient tracking list or waiting lists
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311